BRAF and neoplasm: Recently, selective BRAF inhibitors such as PLX4032 (vemurafenib) and GSK2118436 (dabrafenib) have shown clinical efficacy in BRAF mutant metastatic melanoma patients (Flaherty et al., 2010) with significant tumor regression in approximately 60% of patients (Flaherty et al., 2010).